CRISPR Therapeutics AG
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

Abstract:

A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.